VERILY

Verily Completes Acquisition of SignalPath, Expanding Company’s Clinical Research Capabilities and Marking Company’s First Major Acquisition

Retrieved on: 
Tuesday, August 31, 2021
Health, Technology, Software, Clinical Trials, Networks, Hardware, Trial of the century, Software, Verily, Acquisition, CTMS, Biomarker, Efficiency, Research, Triangle, SPARC, Doctor of Philosophy, Patient, Solution, Technology, MD, Medical imaging, Pharmaceutical industry, Baseline, Verily, SignalPath, BASELINE, VERILY, SIGNALPATH

The SignalPath clinical trials management system (CTMS) brings state-of-the-art software to clinical research sites that improves the ease, quality and efficiency of conducting clinical research.

Key Points: 
  • The SignalPath clinical trials management system (CTMS) brings state-of-the-art software to clinical research sites that improves the ease, quality and efficiency of conducting clinical research.
  • Together, well bring more comprehensive and digital solutions to the clinical trial ecosystem and modernize the way clinical research is conducted.
  • The companys approximately 100 employees will join Verily as part of Verilys clinical research business.
  • The SignalPath Research Consortium (SPARC) consists of top clinical research sites, chosen for their people, processes and track record.

Mayo Clinic, Verily to Build Advanced Clinical Decision Support to Enhance Care

Retrieved on: 
Thursday, August 26, 2021
Nursing, Data Management, Technology, Managed Care, Other Health, Health, General Health, Software, Hospitals, Internet, Hardware, Data science, Knowledge management, Disease management, Center, Forecasting, GPS, Software, Coronavirus, Knowledge, Mayo Clinic, Research, Informatics, Health, Mayo, Caregiver, Health information management, Education, Digital health, Workflow, COVID-19, User-centered design, Technology, Medicine, Medical imaging, Verily, Mayo Clinic, VERILY, MAYO CLINIC

Mayo Clinic will provide curated clinical content rooted in its multidisciplinary and multispecialty practice to Verily.

Key Points: 
  • Mayo Clinic will provide curated clinical content rooted in its multidisciplinary and multispecialty practice to Verily.
  • In turn, Verily will apply advanced clinical analytics and user-centered design to deliver care insights that are integrated into the health care provider workflow.
  • Initially, Mayo Clinic and Verily will focus on a set of cardiovascular and cardiometabolic conditions, with the aim to help guide clinicians toward the highest-quality care.
  • "Mayo Clinic is leading the way in health care informatics and quality of care," says Vivian Lee, M.D., President of Verily Health Platforms.

Verily to Acquire SignalPath, Expanding Company’s Clinical Research Capabilities

Retrieved on: 
Tuesday, August 17, 2021
Data Management, Health, Technology, Software, Clinical Trials, General Health, Ecosystem, Trial of the century, Software, Verily, Acquisition, RWE, CTMS, Biomarker, Efficiency, Research, SPARC, Doctor of Philosophy, Time, Clinical trial, Patient, Solution, Principal, FDA, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Medical imaging, Medical device, Baseline, Verily, SignalPath, BASELINE, VERILY, SIGNALPATH

In addition, the Baseline community now numbers more than 500,000 individuals who are interested in participating in clinical research and automatically matched with research opportunities that meet their interests and profiles.

Key Points: 
  • In addition, the Baseline community now numbers more than 500,000 individuals who are interested in participating in clinical research and automatically matched with research opportunities that meet their interests and profiles.
  • SignalPath was founded in 2014 with a similar goal to change the way that clinical research is conducted, and a specific focus on building state-of-the-art software to improve efficiency for clinical research sites.
  • SignalPath employees will join Verily as part of Verilys clinical research business at the time of closing.
  • The SignalPath Research Consortium (SPARC) consists of top clinical research sites, chosen for their people, processes and track record.

Colgate-Palmolive to Leverage Verily’s Baseline Platform for Innovative Study in Oral Health Research

Retrieved on: 
Friday, August 6, 2021
Cardiology, Data Management, Technology, Diabetes, Health, General Health, Research, Software, Science, Dental, Clinical Trials, Company, Clinical trial, DDS, Duke University School of Medicine, Speed Stick, Prediabetes, Biomarker, Skin, University, Periodontal disease, Connections, MD, PCA, Partnership, Stanford University School of Medicine, Google, Tooth loss, Ajax, Software, Colgate-Palmolive, Multimedia, Leadership, Elmex, General officer, Diabetes, Water, American Heart Association, Overalls, Doctor of Philosophy, PETS, Cardiovascular disease, Academy for Innovative Studies (Evansville), University of North Carolina at Pembroke, Risk, Health, Registry, Google Health, C-reactive protein, Oral hygiene, Policy, Home care in the United States, Axion, Dentistry, Pharmaceutical industry, Colgate-Palmolive Company, Baseline by Verily, Verily, COLGATE-PALMOLIVE COMPANY, BASELINE BY VERILY, VERILY

Under the agreement, Colgate's Dental Clinical Team will partner with Verily to conduct an innovative oral health study as part of Verilys ongoing Baseline Health Study that will aim to improve understanding of connections between oral health and overall human health.

Key Points: 
  • Under the agreement, Colgate's Dental Clinical Team will partner with Verily to conduct an innovative oral health study as part of Verilys ongoing Baseline Health Study that will aim to improve understanding of connections between oral health and overall human health.
  • View the full release here: https://www.businesswire.com/news/home/20210806005031/en/
    Colgate-Palmolive to Leverage Verilys Baseline Platform for Innovative Study in Oral Health Research (Photo: Business Wire)
    The studys goal is to see how oral health practices, including intensive non-surgical periodontal therapy, as well as a robust Colgate home oral hygiene regimen monitored through its hum smart toothbrush connected technologies, affect health more broadly.
  • We are pleased to partner with Colgate, the worlds premier oral care brand, to elucidate the impact of oral health on overall human health, said Amy Abernethy, MD, PhD, president of Verily's clinical research platforms.
  • The Baseline Oral Health Study: UNCoVer the Connections to General Health and has been posted to clinicaltrials.gov .

Verily Appoints Health Data Expert and Former FDA Principal Deputy Commissioner Amy Abernethy, MD, PhD as President of Verily’s Clinical Research Platforms

Retrieved on: 
Thursday, June 3, 2021
Data management, Health, Technology, Clinical trials, Research, Science, Food and Drug Administration, United States Public Health Service, Abernethy, Clinical research, Draft:Amy Abernethy, Health, Darrell Abernethy, Baseline, Verily, BASELINE, VERILY

Verily, an Alphabet company, today announced the appointment of Amy Abernethy, M.D., Ph.D. as President of Verilys clinical research business.

Key Points: 
  • Verily, an Alphabet company, today announced the appointment of Amy Abernethy, M.D., Ph.D. as President of Verilys clinical research business.
  • Verilys clinical research started with the Baseline program, a suite of studies using patient-centric tools for research data collection.
  • As President of this business unit, Dr. Abernethy will oversee this overall product vision and Verilys related clinical research portfolio.
  • Dr. Abernethy was most recently Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agencys acting Chief Information Officer.

Verily Enhances Commercial Organization with the Appointment of Lisa Greenbaum as Chief Revenue Officer

Retrieved on: 
Tuesday, April 27, 2021
Data management, Health, Medical devices, Technology, Other Health, Managed care, Software, San Francisco Bay Area, Companies, Silicon Valley, Alphabet Inc., Verily, Stephen Gillett, Lisa Greenbaum, Chief Revenue Officer, Drew Panayiotou, Chief Marketing Officer, Verily, LISA GREENBAUM, CHIEF REVENUE OFFICER, DREW PANAYIOTOU, CHIEF MARKETING OFFICER, VERILY

b'Verily, an Alphabet company, today announced the appointment of Lisa Greenbaum to the newly-created role of chief revenue officer.

Key Points: 
  • b'Verily, an Alphabet company, today announced the appointment of Lisa Greenbaum to the newly-created role of chief revenue officer.
  • Greenbaum\xe2\x80\x99s appointment builds upon Verily\xe2\x80\x99s January 2021 appointment of Andreas \xe2\x80\x9cDrew\xe2\x80\x9d Panayiotou as chief marketing officer.\n\xe2\x80\x9cThis is an exciting time at Verily as we continue to build out our commercial capabilities to advance innovative, impactful solutions across healthcare,\xe2\x80\x9d said Stephen Gillett, chief operating officer of Verily.
  • \xe2\x80\x9cWe are excited to welcome Lisa who brings more than 25 years of commercial and business development experience to Verily.
  • Prior to Verily, Lisa was chief client officer at Progyny where she led sales, account management, and channel partnerships.

LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression

Retrieved on: 
Monday, April 26, 2021
Medical Supplies, Medical devices, Health, Hospitals, Pharmaceutical, Biotechnology, Clinical research, Health sciences, Medical research, Design of experiments, Health, Clinical trials, Pharmaceutical industry, Placebo-controlled study, Placebo, the RECOVER Study and UNCOVER Sub-study, VNS Therapy for Depression, LivaNova, Verily, THE RECOVER STUDY AND UNCOVER SUB-STUDY, VNS THERAPY FOR DEPRESSION, LIVANOVA, VERILY

The Verily tools measure passive and active data, such as the participant\xe2\x80\x99s pulse rate, activity levels and sleep quality.

Key Points: 
  • The Verily tools measure passive and active data, such as the participant\xe2\x80\x99s pulse rate, activity levels and sleep quality.
  • The double-blind, randomized, placebo-controlled study is assessing how VNS Therapy can offer patients relief from their DTD symptoms and improve quality of life.
  • Symmetry\xc2\xae, the LivaNova VNS Therapy System for depression, is the first and only FDA-approved implantable device specifically designed for DTD.
  • LivaNova and Verily announced their collaboration on UNCOVER in February 2020.\nFor more information on the RECOVER clinical study, please visit www.RecoverVNS.com .